Ligand Pharmaceuticals LGND Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's change in deferred revenue?
- Ligand Pharmaceuticals (LGND) reported change in deferred revenue of $0 in Q1 2026.
- How has Ligand Pharmaceuticals's change in deferred revenue changed year-over-year?
- Ligand Pharmaceuticals's change in deferred revenue increased by 100.0% year-over-year, from -$293K to $0.
- What is the long-term trend for Ligand Pharmaceuticals's change in deferred revenue?
- Over 2 years (2022 to 2024), Ligand Pharmaceuticals's change in deferred revenue has grown at a -55.1% compound annual growth rate (CAGR), from -$6.48M to -$1.31M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.